Content
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
Article By:
ChinaBio® Today
Read
Sunday, November 3, 2019 1:34 AM EDT
BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By:
Benzinga
Read
Friday, November 1, 2019 7:38 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
Defining Reasonable Revenue Growth
Article By:
Early Investing
Read
Sunday, October 27, 2019 9:04 PM EDT
What kind of revenue growth is reasonable for a startup to demonstrate at the early stages? And why are most recent IPOs underperforming?
Meet The Next WeWork: SoftBank's OyO Suffers "Massive Shortfall" After Labor Revolt
Article By:
Tyler Durden
Read
Sunday, October 27, 2019 1:17 AM EDT
Even as Adam Neumann's, and WeWork's, 15 minutes of infamy are almost up, attention on the real mastermind is only now just starting to perk up.
Week In Review: Suzhou's Ascentage Pharma Stages $53 Million IPO In Hong Kong
Article By:
ChinaBio® Today
Read
Saturday, October 26, 2019 9:04 PM EDT
Deals, financings, trials and approvals, and other company news for Chinese companies involved in global biotech.
Is SoftBank The Bubble Era's "Short Of The Century
Article By:
Tyler Durden
Read
Friday, October 25, 2019 10:13 PM EDT
Uber and WeWork were once "among the brightest stars in the SoftBank constellation", prominently displayed in every company presentation, they are now among its worst performers.
WeWork Restructuring Is A Positive Sign For The Markets
Article By:
Zacks Investment Research
Read
Thursday, October 24, 2019 3:45 AM EDT
The restructuring of office sharing prodigy WeWork (WE) is a painful lesson for early investors but it’s actually a sign of health for the IPO markets. Here's why...
TeamViewer IPO Story: If Newsfeed Is Silent, Get Ready For A Buyout
Article By:
ValueWalk
Read
Thursday, October 24, 2019 3:30 AM EDT
Despite the fact that it was one of the largest 2019 IPOs in Europe and that reportedly the IPO was severly oversubscribed, the trading volume has been very low since. In addition to this, the newsfeed on the company is almost completely silent.
Week In Review: Taimei Raises $212 Million For AI Life Science Support Software
Article By:
ChinaBio® Today
Read
Sunday, October 20, 2019 4:00 AM EDT
Deals, financings, trials and approvals in the China bio markets over the past week.
Aramco Again Delays Long-Awaited IPO; Is WeWork To Blame?
Article By:
Tyler Durden
Read
Thursday, October 17, 2019 3:30 PM EDT
After weeks of news that the "zombie" Aramco IPO was set to go public, it is being delayed once again.